IGM-7354

N/A

Report date: 2023/12/15 09:25:36

Base Information

Drug NameIGM-7354

Drug Alias NameAnti-PD-L1 x IL-15 Cytokine Fusion IgMIL-15 x PD-L1 bispecific IgM antibodyIGM-7354

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionInterleukin-15 receptor subunit alpha agonistsAnti-Programmed death-ligand 1

TargetsInterleukin-15 receptor subunit alphaProgrammed death-ligand 1

Therapy Area/IndicationsSolid tumoursHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesIgm Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesIgm Biosciences Inc

Active IndicationsN/A

Inactive IndicationsSolid tumoursHematologic Neoplasms

Other Information

ATC CodeN/A